Invesco Ltd. Sells 23,515 Shares of Theravance Biopharma, Inc. $TBPH

Invesco Ltd. reduced its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 51.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,535 shares of the biopharmaceutical company's stock after selling 23,515 shares during the quarter. Invesco Ltd.'s holdings in Theravance Biopharma were worth $201,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. GSA Capital Partners LLP increased its stake in Theravance Biopharma by 11.9% in the 1st quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company's stock worth $1,628,000 after buying an additional 19,363 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock worth $556,000 after purchasing an additional 2,293 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Theravance Biopharma by 16.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company's stock worth $610,000 after purchasing an additional 9,315 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Theravance Biopharma by 1.5% in the first quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock worth $1,049,000 after purchasing an additional 1,720 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in shares of Theravance Biopharma in the fourth quarter worth about $119,000. 99.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

TBPH has been the topic of several analyst reports. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a research note on Tuesday, June 17th. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 16th. BTIG Research boosted their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, June 27th. Finally, Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 15th. Two research analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Strong Buy" and a consensus price target of $21.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $13.92 on Tuesday. The firm has a market capitalization of $701.01 million, a price-to-earnings ratio of 58.00 and a beta of 0.04. The stock has a 50 day moving average price of $12.17 and a 200 day moving average price of $10.48. Theravance Biopharma, Inc. has a 52-week low of $7.88 and a 52-week high of $14.55.

Insiders Place Their Bets

In other news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the sale, the senior vice president owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.